Clinical and genetic study of a large CharcotMarieTooth type 2A family from southern Italy
M. Muglia, PhD;,
M. Zappia, MD;,
V. Timmerman, PhD;,
P. Valentino, MD,
A. L. Gabriele, PhD,
F. L. Conforti, PhD,
P. De Jonghe, MD, PhD,
M. Ragno, MD;,
R. Mazzei, PhD,
M. Sabatelli, MD;,
G. Nicoletti, MD,
A. M. Patitucci, PhD,
R. L. Oliveri, MD, MSc,
F. Bono, MD,
A. Gambardella, MD and
A. Quattrone, MD
From the Institute of Experimental Medicine and Biotechnology (Drs. Muglia, Gabriele, Conforti, Mazzei, Patitucci, Oliveri, Gambardella, and Quattrone), National Research Council, Piano Lago di MangoneCosenza; Institute of Neurology (Drs. Zappia, Valentino, Oliveri, Bono, Gambardella, and Quattrone), School of Medicine, Catanzaro; Institute of Neurology (Dr. Ragno), Hospital G. e C. Mazzoni, Ascoli Piceno; Institute of Neurology (Dr. Sabatelli), Catholic University, Rome, Italy; and Flanders Interuniversity Institute for Biotechnology (VIB) (Dr. Timmerman), BornBunge Foundation (BBS), University of Antwerpen (UIA), Antwerpen, Belgium.
Figure. Pedigree of the Italian CharcotMarieTooth type 2 (CMT2) family, showing the haplotypes of the patients. Circles = women; squares = men; slashed symbols = deceased individuals; filled symbols = affected individuals; open symbols = unaffected individuals; shaded symbols = disease status unknown; black bars = disease haplotype linked to CMT2A.